Federal judge dismisses compounded GLP-1 antitrust suit against Lilly and Novo

A federal judge in San Antonio has thrown out a compounding pharmacy's antitrust lawsuit against Eli Lilly and Novo Nordisk, concluding that compounded GLP-1 medicines do not compete in the same market as the manufacturers' branded products ^[1][4].

U.S. District Judge Micaela Alvarez of the Western District of Texas granted dismissal motions from both drugmakers, ending the case Strive Specialties Inc. filed on Jan. 14, 2026 ^[1][5]. The dismissal was with prejudice, so the same claims cannot simply be refiled ^[4]. The order is dated Aug. 5, 2026 ^[4][5]; Reuters reported the ruling on Aug. 6 ^[1].

Strive, an Arizona-based compounding pharmacy, claimed Lilly and Novo locked up the telehealth channel through exclusive contracts ^[2][4]. Under those arrangements, according to the complaint, clinicians working with major telehealth platforms were barred from arranging compounded GLP-1s even when they had written a prescription for one ^[1][4]. Strive brought a monopolization count against Lilly under Section 2 of the Sherman Act, plus claims against both companies under Section 1 of the Sherman Act and Section 3 of the Clayton Act ^[4]. It argued that telehealth accounts for roughly half of cash-pay GLP-1 prescriptions, and said compounders supplied about 10 percent of the cash market for those drugs ^[4][5]. It asked the court to block the arrangements and to restore competitive conditions ^[2].

Alvarez's ruling turned on market definition, a threshold requirement in antitrust cases ^[4]. Strive proposed a nationwide market for GLP-1 drugs plus a submarket limited to cash-paying patients ^[4]. The judge held that both were drawn too broadly, because federal law generally lets a compounder fill a compounded prescription only after a prescriber determines an approved product cannot meet that patient's particular needs ^[1][4]. That makes the two kinds of medicine not reasonably interchangeable, the court said, and without a valid market the claims cannot proceed ^[1][4].

The court also concluded that the harm Strive described amounted to its own business loss rather than damage to competition, writing that "antitrust laws protect competition — not individual competitors — and losses attributable to ordinary competitive forces do not suffice" ^[1].

Strive said it was disappointed, noted that certain state attorneys general had raised questions about how the drugmakers handled the case, and said it is evaluating options including an appeal ^[1]. Lilly said "this meritless claim should have never been brought against Lilly" and that the ruling "confirms that companies mass compounding tirzepatide are violating the law" ^[1]. Novo said it is "pleased with the court's decision to dismiss all claims against Novo Nordisk" ^[1].

The dispute sits inside a broader fight. Demand for Novo's Ozempic and Wegovy and Lilly's Mounjaro and Zepbound surged, and compounding pharmacies made their own versions while the drugs were listed as short in supply ^[1]. The FDA ended the shortage designation for Lilly's GLP-1 drugs in December 2024 and gave compounders 60 to 90 days to stop producing copies ^[2]. In January 2026, Novo chief executive Mike Doustdar estimated that about 1.5 million U.S. patients were using compounded versions of the company's GLP-1s ^[2].

Why it matters for patients

The ruling leaves the telehealth contracts Strive challenged in place; no court order now blocks them ^[1][4]. A compounded GLP-1 is not an FDA-approved product ^[2]. Federal rules generally permit one only when a prescriber finds an approved drug will not work for that patient, and outside a declared shortage pharmacists may not turn out what amount to copies of approved medicines ^[4][5]. Where a patient can get a compounded version therefore depends on the individual prescriber's judgment, the policies of whichever telehealth service is involved and FDA shortage decisions, not on this lawsuit ^[1][4]. The order does not change the approval status of Ozempic, Wegovy, Mounjaro or Zepbound ^[4][5]. GLP-1 sales topped $40 billion in 2025 and branded prices ran above $1,000 a month, according to figures cited in Strive's complaint ^[5].

What happens next

Strive said it is evaluating its options, including an appeal; no appeal had been reported as of Aug. 6 ^[1]. Because the dismissal was with prejudice, any renewed effort would likely have to come through an appellate court or a new case built on different facts ^[4]. Strive pointed to interest from state attorneys general, but no state case against the companies over these contracts has been reported ^[1].